HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2025)
HUTCHMED (China)'s (HCM) quarterly Total Non-Current Liabilities came in at $51.3 million in Q4 2025, down 16.87% year-on-year from $61.7 million in Q4 2024, and down 88.36% on a QoQ basis from $441.0 million in Q2 2025.
HUTCHMED (China) (HCM) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 11 years of Total Non-Current Liabilities data on file, last reported at $51.3 million in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 16.87% year-over-year to $51.3 million in Q4 2025; TTM through Dec 2025 was $51.3 million, a 16.87% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, up 28.69% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $51.3 million, down from $441.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for HCM reached as high as $489.5 million in Q2 2024 and fell as low as -$2.8 billion in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged -$39.8 million across 5 years, with a median of $221.9 million in 2021.
- Across the five-year window, Total Non-Current Liabilities surged 774.28% in 2021 and slumped 6148.6% in 2023, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $35.8 million in 2021, then surged by 31.16% to $47.0 million in 2022, then tumbled by 6148.6% to -$2.8 billion in 2023, then surged by 102.17% to $61.7 million in 2024, then fell by 16.87% to $51.3 million in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $51.3 million in Q4 2025, $441.0 million in Q2 2025, and $61.7 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | HUTCHMED (China) | 241.90 Mn | 243.61 Mn | - | 51.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.32 Mn |
| Jun 30, 2025 | 440.98 Mn |
| Dec 31, 2024 | 61.74 Mn |
| Jun 30, 2024 | 489.55 Mn |
| Dec 31, 2023 | -2.84 Bn |
| Jun 30, 2023 | 478.19 Mn |
| Dec 31, 2022 | 46.96 Mn |
| Jun 30, 2022 | 322.27 Mn |
| Dec 31, 2021 | 35.81 Mn |
| Jun 30, 2021 | 253.67 Mn |
| Mar 31, 2021 | 221.92 Mn |
| Dec 31, 2020 | 16.03 Mn |
| Jun 30, 2020 | -37.62 Mn |
| Dec 31, 2019 | 6.07 Mn |
| Sep 30, 2019 | 108.85 Mn |
| Jun 30, 2019 | 114.32 Mn |
| Mar 31, 2019 | 130.61 Mn |
| Dec 31, 2018 | 117.46 Mn |
| Jun 30, 2018 | 117.25 Mn |
| Dec 31, 2017 | -18.75 Mn |